NIMH Offering $6M Next Year for Depression Biomarkers | GenomeWeb

NEW YORK (GenomeWeb News) – The National Institute of Mental Health will provide around $6 million and up to $24 million over four years to support researchers seeking biomarkers that could be used in predicting patient response to depression drugs.

The Biosignature Discovery for Personalized Treatment in Depression grant program will fund one or more projects that aim to identify a personalized treatment algorithm which will be tested in a future clinical trial, and will support a sample resource from depression patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.